A recent study by Ulpiano et al., published in Stem Cell Research & Therapy (2025), presents a fully scalable, Good Manufacturing Practice (GMP)-compliant platform for producing extracellular vesicles (EVs) derived from human mesenchymal stromal cells (MSCs). The platform uses microcarrier-based stirred-tank reactors (STRs) combined with advanced purification methods to enable continuous, large-scale production of [...]

Published in the Journal of Extracellular Vesicles, May 2024 Lead author: Dr. Gagandeep Kaur A study published in the Journal of Extracellular Vesicles reports that extracellular vesicles (EVs) derived from mesenchymal stem/stromal cells (MSCs) using microcarrier-based cultures are more effective in suppressing immune responses than those from conventional monolayer cultures. The researchers also found that [...]

As we age, hearing loss becomes more common—and frustrating. It’s not just about turning up the volume; it’s about tiny, delicate cells in our ears that get damaged and don’t grow back. Scientists are now exploring how stem cells and their “messenger bubbles” (called EVs) might actually help the body repair itself. This could [...]

RoosterBio, Inc. recently hosted a webinar titled Exploring MSC-EV Attributes: Analytical Comparison of Tissue Sources & Production Platforms. In this session, Dr. Elie Zakhem (Associate Director, Analytical Development and Services) and Dr. Stephen Lenzini (Senior Scientist) presented key insights on how different tissue sources and production platforms shape the characteristics of mesenchymal stem cell [...]

Smart MCs is a partner in the newly launched Additive Manufacturing Cooperative Research Centre (AMCRC) — a $271 million national initiative focused on transforming and strengthening Australia’s manufacturing capabilities through additive manufacturing (3D printing).The AMCRC brings together more than 100 organisations from across research, industry, and government. Some of the key partners include:BoeingCSIRORMIT UniversityUniversity of [...]

Smart MCs is proud to be a core partner in the $238 million SMART CRC (Solutions for Manufacturing Advanced Regenerative Therapies), a new national research centre hosted by The University of Queensland. This transformative initiative brings together more than 60 partners from across Australia’s research, biotech, and healthcare sectors to advance the way regenerative [...]

The United States Food and Drug Administration (FDA) recently announced a significant policy change. The FDA plans to phase out its requirement for animal testing in the safety evaluation of certain medicines, including monoclonal antibodies (mAbs). This change reflects the FDA’s effort to update drug testing practices with methods that are more relevant to human [...]

The following protocols for isolating Mesenchymal Stem Cells (MSCs) are adapted and simplified by FUJIFILM Irvine Scientific from published reports. Please note that these protocols have not been validated by Smart MCs and are provided for reference purposes only. For additional MSC-related protocols and reagents, please visit the FUJIFILM Irvine Scientific website. You can [...]

We are pleased to announce that Smart MCs will be exhibiting at the Advanced Therapies Congress 2025, taking place on March 18-19, 2025, at ExCeL London. Recognised as Europe’s largest commercial cell and gene therapy event, this congress is a key meeting point for experts, researchers, and industry leaders who are shaping the future [...]